14.08
-1.19%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Mediwound
Its shares trade under the ticker MDWD. It has been listed since 20 March 2014. In the fiscal year to 31 December 2025, it reported revenue of $17.0m and a net loss of $23.9m. At that date it held total assets of $86.3m and shareholders' equity of $43.6m.
MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. The firm focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The firm's product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns. The firm sells NexoBrid in Europe and Israel. NexoBrid is a topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. Its product, EscharEx, is a topical biological drug, which is being developed for debridement of chronic and other hard-to-heal wounds. NexoBrid and EscharEx are based on its proteolytic enzyme technology. The firm is also developing an injectable product based on its proteolytic enzyme technology for connective tissue pathologies and indications.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 20 Mar 2014
- Employees
- 121
- Website
- mediwound.com ↗
- Head office
- 42 HAYARKON STREET, YAVNE, L3, 8122745
- Incorporated in
- L3
- Classification
- Medicinal Chemicals & Botanical Products
- Filer status
- Accelerated filer
Leadership
Pay as last reported
- Mr. Nachum ShamirIndependent Chairman of the Board
- Mr. Ofer GonenChief Executive Officer, Director, since 2003$1.8m
- Ms. Hani LuxenburgChief Financial Officer$558,000
- Dr. Shmulik HessChief Operating Officer, Chief Commercial Officer$695,000
- Mr. Yaron MeyerExecutive Vice President, General Counsel, Corporate Secretary$449,000
- Dr. Ety KlingerChief Research and Development Officer$543,000
- Dr. Robert SnyderChief Medical Officer
- Dr. Vickie DriverIndependent Director
- Mr. David FoxIndependent Director
- Mr. Shmuel RubinsteinIndependent Director
- Mr. Stephen WillsIndependent Director, since 2017
- Mr. Jeremy FefferManaging Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 31
- Environment
- 4
- Social
- 32
- Governance
- 58
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Mediwound Ltd possesses several strengths that contribute to its success in the market. The company's advanced wound care products and technologies lead the industry, providing innovative solutions for various types of wounds. Furthermore, Mediwound's strong research and development capabilities enable continuous product improvement and expansion, strengthening its competitive advantage. The company's extensive experience in the wound care market and established relationships with healthcare professionals and key stakeholders further enhance its market position.
Weaknesses
- Despite its strengths, Mediwound Ltd faces certain weaknesses that pose challenges. The company heavily relies on a limited range of products, which may make it vulnerable to market shifts or changes in customer preferences. Additionally, Mediwound's dependency on external suppliers for raw materials and manufacturing processes can disrupt the supply chain, potentially impacting production and delivery timelines. Addressing these weaknesses through diversification strategies and supplier management is crucial for sustained success.
Opportunities
- Mediwound Ltd operates in an industry with several growth opportunities. The increasing prevalence of chronic wounds and rising healthcare expenditure present an expanding market for Mediwound's wound care solutions. The company can seize the opportunity to expand its product portfolio and diversify into new markets and segments, such as diabetic wound care or regenerative medicine. Moreover, partnerships or collaborations with healthcare organizations and research institutions can fuel innovation and provide access to untapped markets.
Threats
- Mediwound Ltd also faces threats that could affect its business operations. Intense competition within the wound care industry, where numerous well-established players exist, poses challenges for market share and pricing. Additionally, regulatory requirements and compliance measures may increase operational costs and restrict product development or approval processes. The potential emergence of alternative therapies or disruptive technologies could also impact Mediwound's market position. Continual monitoring of the competitive landscape and adapting swiftly to regulatory changes is essential to mitigate threats effectively.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.